Amplitude for A/L = 0.02. by Muhammad Hammad Bucha (21736111)

Subjects:

Amplitude for A/L = 0.03. by Muhammad Hammad Bucha (21736111)

Subjects:

Study area and sites with <i>Ae</i>. <i>albopictus</i> occurrences between 2014 and 2018 in the LNP. by Judicaël Obame-Nkoghe (3512054)

Subjects:

S5 Fig - by Meghan J. Hirsch (16528311)

VAMP2 decreases 5-HT uptake and SERT cell surface expression in HEK-293 MSR cells by reducing the delivery rate of the transporter to the plasma membrane. by Heidi Kaastrup Müller (570207)

Overexpression of PR decreases Myc expression and activity. by Tamar Kavlashvili (849072)

Potassium depletion of Huh-7 cells results in a similar mitochondrial oxygen consumption rate and a moderately decreased extracellular acidification rate. by John W. Murray (2841077)

Fig 5 - by Mykola Pinkevych (125551)

The primer information. by Guangxiao Ni (19713106)

Subjects:

Evans Blue extravasation between groups. by Guangxiao Ni (19713106)

Subjects:

Decreased Na_v1.5 expression in <i>Scn5a</i>^+/− mice. by Anne-Laure Leoni (366926)

The 5-point summary of CPM dataset. by Gaurav Sandeep Dave (21519884)

Activation of mGluR5 site-specifically decreases spine density in the nucleus accumbens. by Kellie S. Gross (3115299)

Average giving in the 5€, 100€, and 1000€ treatments. by Pablo Brañas-Garza (336425)

Overexpression of miR132 decreases synaptic depression in response to a train of stimuli, but does not affect the rate of refilling of the RRP. by Talley J. Lambert (358201)

Loss of Rumi leads to intracellular accumulation and decreased IRS levels of Eys in a temperature dependent manner at the mid-pupal stage. by Amanda R. Haltom (664189)

“…The scale bar in A applies to A–G′ and is 5 µm. (A,A′) A wild-type ommatidium at 55% PD raised at 18°C. …”

RGS5 deletion resulted in decreased peripheral insulin sensitivity and suppressed the Akt/GSK3β signaling pathway in mice fed an HF for 24 weeks. by Wei Deng (17330)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

Supplementary Material for: Platelet Decreases following Continuous Renal Replacement Therapy Initiation as a Novel Risk Factor for Renal Nonrecovery by Griffin B.R. (8570007)

Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)